{"id":"NCT00937391","sponsor":"Bayer","briefTitle":"Contrast-enhanced MRI in Children 2 Months to <2 Years","officialTitle":"Open-label, Multi-center, Two-stage, Age Stratified, Pharmacokinetic, Safety, and Efficacy Study in Children 2 Months to < 2 Years of Age Undergoing Magnevist Injection Enhanced MRI","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2009-07-13","resultsPosted":"2011-10-13","lastUpdate":"2015-11-18"},"enrollment":54,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Magnetic Resonance Imaging"],"interventions":[{"type":"DRUG","name":"Gadopentetate dimeglumine (Magnevist, BAY86-6661)","otherNames":[]}],"arms":[{"label":"Gadopentetate dimeglumine (Magnevist, BAY86-6661)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to \\< 2 years of age","primaryOutcome":{"measure":"Number of Participants With Diagnostic Adequacy - Open-label Clinical Investigators (Per Protocol Set)","timeFrame":"Within 5 minutes after injection","effectByArm":[{"arm":"Gadopentetate Dimeglumine - Stage 1 (Comb. Image 0.05 mmol/kg)","deltaMin":1,"sd":null},{"arm":"Gadopentetate Dimeglumine - Stage 1 (Comb. Image 0.1 mmol/kg)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":13,"countries":["United States","Germany"]},"refs":{"pmids":[],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":20},"commonTop":["Pyrexia","Vomiting","Inappropriate antidiuretic hormone secretion","Rhinitis","Convulsion"]}}